Cytokinetics' Heart Drug Gains FDA Approval, Boosting Its Market Edge
TL;DR Summary
Cytokinetics received FDA approval for its first drug, Myqorzo, to treat obstructive hypertrophic cardiomyopathy, ending a 27-year R&D drought for the company. The drug will compete with a similar medication from Bristol Myers Squibb and is expected to launch in late January.
- Cytokinetics heart drug wins FDA approval, the biotech’s first statnews.com
- Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms Cytokinetics
- US FDA approves Cytokinetics' heart disease drug Reuters
- Cytokinetics Has Doubled Since May. Does It Still Have Steam? Investor's Business Daily
- FDA approves Cytokinetics’ heart drug, giving it an edge over BMS rival Endpoints News
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
86%
294 → 42 words
Want the full story? Read the original article
Read on statnews.com